An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.
Identifieur interne : 002C66 ( PubMed/Corpus ); précédent : 002C65; suivant : 002C67An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.
Auteurs : Elisabetta Traggiai ; Stephan Becker ; Kanta Subbarao ; Larissa Kolesnikova ; Yasushi Uematsu ; Maria Rita Gismondo ; Brian R. Murphy ; Rino Rappuoli ; Antonio LanzavecchiaSource :
- Nature medicine [ 1078-8956 ] ; 2004.
English descriptors
- KwdEn :
- Adult, Animals, Antibodies, Monoclonal (isolation & purification), B-Lymphocytes (immunology), Chlorocebus aethiops, DNA Primers, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Herpesvirus 4, Human (metabolism), Humans, Immunization, Passive (methods), Immunologic Memory (immunology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (metabolism), Mice, Microscopy, Immunoelectron, Neutralization Tests, Polymerase Chain Reaction, Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, Transformation, Genetic, Vero Cells, Viral Envelope Proteins (genetics), Viral Envelope Proteins (metabolism), alpha-Macroglobulins (metabolism).
- MESH :
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , isolation & purification : Antibodies, Monoclonal.
- immunology : B-Lymphocytes, Immunologic Memory, Severe Acute Respiratory Syndrome.
- metabolism : Herpesvirus 4, Human, Membrane Glycoproteins, Viral Envelope Proteins, alpha-Macroglobulins.
- methods : Immunization, Passive.
- Adult, Animals, Chlorocebus aethiops, DNA Primers, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Microscopy, Immunoelectron, Neutralization Tests, Polymerase Chain Reaction, Spike Glycoprotein, Coronavirus, Transformation, Genetic, Vero Cells.
Abstract
Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.
DOI: 10.1038/nm1080
PubMed: 15247913
Links to Exploration step
pubmed:15247913Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.</title>
<author><name sortKey="Traggiai, Elisabetta" sort="Traggiai, Elisabetta" uniqKey="Traggiai E" first="Elisabetta" last="Traggiai">Elisabetta Traggiai</name>
<affiliation><nlm:affiliation>Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Becker, Stephan" sort="Becker, Stephan" uniqKey="Becker S" first="Stephan" last="Becker">Stephan Becker</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
<author><name sortKey="Kolesnikova, Larissa" sort="Kolesnikova, Larissa" uniqKey="Kolesnikova L" first="Larissa" last="Kolesnikova">Larissa Kolesnikova</name>
</author>
<author><name sortKey="Uematsu, Yasushi" sort="Uematsu, Yasushi" uniqKey="Uematsu Y" first="Yasushi" last="Uematsu">Yasushi Uematsu</name>
</author>
<author><name sortKey="Gismondo, Maria Rita" sort="Gismondo, Maria Rita" uniqKey="Gismondo M" first="Maria Rita" last="Gismondo">Maria Rita Gismondo</name>
</author>
<author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name>
</author>
<author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15247913</idno>
<idno type="pmid">15247913</idno>
<idno type="doi">10.1038/nm1080</idno>
<idno type="wicri:Area/PubMed/Corpus">002C66</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.</title>
<author><name sortKey="Traggiai, Elisabetta" sort="Traggiai, Elisabetta" uniqKey="Traggiai E" first="Elisabetta" last="Traggiai">Elisabetta Traggiai</name>
<affiliation><nlm:affiliation>Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Becker, Stephan" sort="Becker, Stephan" uniqKey="Becker S" first="Stephan" last="Becker">Stephan Becker</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
<author><name sortKey="Kolesnikova, Larissa" sort="Kolesnikova, Larissa" uniqKey="Kolesnikova L" first="Larissa" last="Kolesnikova">Larissa Kolesnikova</name>
</author>
<author><name sortKey="Uematsu, Yasushi" sort="Uematsu, Yasushi" uniqKey="Uematsu Y" first="Yasushi" last="Uematsu">Yasushi Uematsu</name>
</author>
<author><name sortKey="Gismondo, Maria Rita" sort="Gismondo, Maria Rita" uniqKey="Gismondo M" first="Maria Rita" last="Gismondo">Maria Rita Gismondo</name>
</author>
<author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name>
</author>
<author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
</author>
</analytic>
<series><title level="j">Nature medicine</title>
<idno type="ISSN">1078-8956</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Animals</term>
<term>Antibodies, Monoclonal (isolation & purification)</term>
<term>B-Lymphocytes (immunology)</term>
<term>Chlorocebus aethiops</term>
<term>DNA Primers</term>
<term>Disease Models, Animal</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Herpesvirus 4, Human (metabolism)</term>
<term>Humans</term>
<term>Immunization, Passive (methods)</term>
<term>Immunologic Memory (immunology)</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (metabolism)</term>
<term>Mice</term>
<term>Microscopy, Immunoelectron</term>
<term>Neutralization Tests</term>
<term>Polymerase Chain Reaction</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Transformation, Genetic</term>
<term>Vero Cells</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (metabolism)</term>
<term>alpha-Macroglobulins (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>B-Lymphocytes</term>
<term>Immunologic Memory</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Herpesvirus 4, Human</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
<term>alpha-Macroglobulins</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Passive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>DNA Primers</term>
<term>Disease Models, Animal</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Humans</term>
<term>Mice</term>
<term>Microscopy, Immunoelectron</term>
<term>Neutralization Tests</term>
<term>Polymerase Chain Reaction</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Transformation, Genetic</term>
<term>Vero Cells</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15247913</PMID>
<DateCompleted><Year>2004</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN>
<JournalIssue CitedMedium="Print"><Volume>10</Volume>
<Issue>8</Issue>
<PubDate><Year>2004</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Nature medicine</Title>
<ISOAbbreviation>Nat. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>871-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Traggiai</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Becker</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Subbarao</LastName>
<ForeName>Kanta</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kolesnikova</LastName>
<ForeName>Larissa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Uematsu</LastName>
<ForeName>Yasushi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gismondo</LastName>
<ForeName>Maria Rita</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Murphy</LastName>
<ForeName>Brian R</ForeName>
<Initials>BR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rappuoli</LastName>
<ForeName>Rino</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lanzavecchia</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2004</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Nat Med</MedlineTA>
<NlmUniqueID>9502015</NlmUniqueID>
<ISSNLinking>1078-8956</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000511">alpha-Macroglobulins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C032306">polyclonal B cell activator</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014170" MajorTopicYN="N">Transformation, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000511" MajorTopicYN="N">alpha-Macroglobulins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year>
<Month>11</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>7</Month>
<Day>13</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>7</Month>
<Day>13</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId>
<ArticleId IdType="doi">10.1038/nm1080</ArticleId>
<ArticleId IdType="pii">nm1080</ArticleId>
<ArticleId IdType="pmc">PMC7095806</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Immunol. 2000 Jan 15;164(2):944-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10623843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 1988 Oct;26(2):153-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3183639</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 1997 Nov;176(5):1215-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9359721</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Med Microbiol Immunol. 1992;181(1):43-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1579085</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1991 Jul;183(1):225-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1711257</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2003 Jan;2(1):52-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12509759</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Microbiol Rev. 2000 Oct;13(4):602-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11023960</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1799-804</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11172031</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hybridoma. 1982;1(3):323-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6092264</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1761-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781533</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 1981 Oct;127(4):1275-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6268704</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1990 Dec 6;348(6301):552-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2247164</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1975 Aug 7;256(5517):495-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1172191</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Oct;77(19):10394-403</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12970424</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2002 Dec 13;298(5601):2199-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12481138</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2000 Jan 31;18(14):1412-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10618539</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 1999 Dec 10;231(1-2):11-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10648924</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Dtsch Med Wochenschr. 1965 Dec 3;90(49):2183</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5843503</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 1995 Mar 1;181(3):1245-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7869042</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1986 May 29-Jun 4;321(6069):522-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3713831</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1985 Apr 11-17;314(6011):537-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3157869</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1977 Sep 29;269(5627):420-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">198669</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002C66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:15247913 |texte= An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15247913" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |